Chembox Hazards MainHazards FlashPt Autoignition Torcetrapib CP 529,414, Pfizer was a medication ... mortality in the treatment group receiving a combination of atorvastatin Lipitor and torcetrapib. Mechanism Torcetrapib acts as a CETP inhibitor by inhibiting cholesterylester transfer protein CETP ... release title Pfizer Begins Production at Torcetrapib Atorvastatin Manufacturing Facility publisher ... accessdate 2006 12 03 ref Pfizer had previously announced that torcetrapib would be sold in combination ..., Pfizer had subsequently planned for torcetrapib to be sold independently of Lipitor. ref cite news ... 12 03 ref Clinical trials A 2004 trial 19 subjects, non randomised showed that torcetrapib could increase ... ct2 results?term torcetrapib ref ref http clinicaltrials.gov ct2 show NCT00139061 Phase III Assess HDL C Increase And Non HDL Lowering Effect Of Torcetrapib Atorvastatin Vs. Fenofibrate ref ref http clinicaltrials.gov ct2 show NCT00134511 Phase III Study To Evaluate The Effect Of Torcetrapib ... show NCT00134485 Phase III Study To Evaluate The Safety And Efficacy Of Torcetrapib Atorvastatin In Subjects ... III Study Comparing The Efficacy & Safety Of Torcetrapib Atorvastatin And Atorvastatin In Subjects ... Comparing Torcetrapib Atorvastatin To Simvastatin In Subjects With High Cholesterol ref ref http clinicaltrials.gov ct2 show NCT00138762 Phase III Study of Torcetrapib Atorvastatin vs Atorvastatin Alone ... Phase III Coronary IVUS Study to Compare Torcetrapib Atorvastatin to Atorvastatin Alone in Subjects ... of study On December 2, 2006 Pfizer cut off torcetrapib s phase III trial because of an imbalance ... trial, a 60 increase in deaths was observed among patients taking torcetrapib and atorvastatin ... link date October 2010 bot H3llBot Each study arm torcetrapib atorvastatin vs. atorvastatin alone had ... in the torcetrapib atorvastatin arm. Link dead as of 15 January 2007 ref Pfizer recommended that all ... Torcetrapib showed no clinical benefit in this or other studies, and will not be developed further ... more details
File Torcetrapib.png thumb Torcetrapib File Anacetrapib.svg thumb Anacetrapib File JTT 705 structure.png thumb Dalcetrapib A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein CETP . ref name pmid17387130 cite journal author Tall AR title CETP inhibitors to increase HDL cholesterol levels journal N. Engl. J. Med. volume 356 issue 13 pages 1364 6 year 2007 month March pmid 17387130 doi 10.1056 NEJMe078029 url http content.nejm.org cgi pmidlookup?view short&pmid 17387130&promo ONFLNS19 ref ref name pmid18536741 cite journal author Joy TR, Hegele RA title The failure of torcetrapib what have we learned? journal Br. J. Pharmacol. volume 154 issue 7 pages 1379 81 year 2008 month August pmid 18536741 doi 10.1038 bjp.2008.248 pmc 2492099 ref ref name pmid18808319 cite journal author Rennings AJ, Stalenhoef AF title JTT 705 is there still future for a CETP inhibitor after torcetrapib? journal Expert Opin Investig Drugs volume 17 issue 10 pages 1589 97 year 2008 month October pmid 18808319 doi 10.1517 13543784.17.10.1589 url http www.expertopin.com doi abs 10.1517 13543784.17.10.1589 ref ref cite journal author Carmen Drahl title The Cholesterol Bet journal Chemical & Engineering News volume 90 issue 8 pages 13 20 year 2012 month February url http cen.acs.org articles 90 i8 Cholesterol Bet.html ref They are intended to reduce the risk of atherosclerosis a cardiovascular disease by improving blood lipid levels. Examples include Torcetrapib , failed in 2006 excess deaths in phase III. Anacetrapib , encouraging phase IIb interim results in 2010. Two phase III trials are running in 2012. Dalcetrapib , in phase III in 2012. Evacetrapib , phase II study results published in November 2011 ref cite journal author Stephen J. Nicholls et al. title Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial journal JAMA volume 306 issue 19 pages 2099 ... more details
the problems with torcetrapib, it is thought that CETP inhibitors are still likely to be useful in the treatment ... journal author Joy T, Hegele RA title The end of the road for CETP inhibitors after torcetrapib? journal ... more details
molecular agent torcetrapib was shown to increase HDL levels, alone and with a statin , and lower ... , no change in atherosclerosis, ref cite journal year 2007 month March title Effect of torcetrapib ... cite journal year 2007 month April title Effect of torcetrapib on carotid atherosclerosis in familial ... Riley first9 Ward A. ref and, in a trial of a combination of torcetrapib and atorvastatin , an increase ... All Torcetrapib Clinical Trials in Interest of Patient Safety publisher U.S. Food and Drug Administration ... to torcetrapib, Dalcetrapib investigative name JTT 705 R1658 , is also being studied. ref cite journal ... to 60 by torcetrapib. ref cite journal author de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de ... more details
show the same increase in adverse cardiovascular events that was seen with torcetrapib. Fortunately ... date January 30, 2012 ref See also Torcetrapib , another CETP inhibitor, which was developed ... more details
orphan date December 2007 Refimprove date September 2007 This list of pharmaceutical compound number prefixes details a drug labeling standard. Pharmaceutical companies produce a large number of compounds. The compounds are systematically numbered, such as CP 529414 for the recently failed Pfizer experimental drug torcetrapib . In addition to the number, there are several letters the prefix that usually tells which company the compound comes from. Since the pharmaceutical industry has gone through a lot of mergers and acquisitions, the original company and the current company are both listed. A to F ABT Abbott Labs ACP Acadia Phamarceuticals ACZ Novartis ADL Adolor Corporation ref cite web url http www.portfolio.com resources company profiles ADLR press 2007 12 28 adolor announces investigational new drug application for novel delta agonist adl5747 title ADL5747 accessdate 2008 03 19 Dead link date October 2010 bot H3llBot ref AG Agouron , now Pfizer La Jolla Labs AH Amersham plc Amersham Health ALS Alantos Pharmaceuticals , acquired by Amgen in June 2007 ANX Adventrx Pharmaceuticals ref cite web url http www.adventrx.com products title Adventrx Product List accessdate 2007 11 18 ref AMG Amgen ARQ ArQule ATL Antisense Therapeutics Limited, Australia ref cite web url http www.antisense.com.au title Antisense Therapeutics Ltd Home Page accessdate 2008 02 20 ref AZD AstraZeneca BMS Bristol Myers Squibb BRL Beecham pharmaceutical company Beecham Research Labs , merged with SmithKline into SmithKline Beecham which merged into GlaxoSmithKline CAT Cannasat Therapeutics Inc. CC Celgene CE Pfizer CGS Ciba Geige CP Pfizer Groton. CP probably refer to the founder of the company, Charles Pfizer CSL CSL Limited , an Australian Biophamaceutical company CVX CovX, acquired by Pfizer in 2008 DMP DuPont Merck Pharmaceuticals , a joint venture between DuPont and Merck & Co. Merck , turns to DuPont Pharmaceuticals in 1998 DPC DuPont Pharmaceuticals , acquired by Bristol Myers Squibb in ... more details
For the journal Atherosclerosis journal Infobox disease Name Atherosclerosis Image Endo dysfunction Athero.PNG Caption The progression of atherosclerosis size exaggerated see text DiseasesDB 1039 ICD10 ICD10 I 70 i 70 ICD9 ICD9 440 , ICD9 414.0 MedlinePlus 000171 eMedicineSubj med eMedicineTopic 182 MeshID D050197 Atherosclerosis also known as arteriosclerotic vascular disease or ASVD is a condition in which an artery wall thickens as a result of the accumulation of fatty materials such as cholesterol . It is a syndrome affecting artery arterial blood vessel s, a chronic inflammatory response in the walls of arteries, caused largely by the accumulation of macrophage white blood cells and promoted by low density lipoprotein s plasma proteins that carry cholesterol and triglycerides without adequate removal of fats and cholesterol from the macrophages by functional high density lipoprotein s HDL , see apoA 1 Milano . It is commonly referred to as a hardening or furring of the arteries. It is caused by the formation of multiple atheroma plaques within the arteries. ref cite book last Maton first Anthea authorlink coauthors Roshan L. Jean Hopkins, Charles William McLaughlin, Susan Johnson, Maryanna Quon Warner, David LaHart, Jill D. Wright title Human Biology and Health publisher Prentice Hall year 1993 location Englewood Cliffs, NJ isbn 0 13 981176 1 oclc 32308337 ref The atheroma atheromatous plaque is divided into three distinct components The atheroma lump of gruel, from , athera , gruel in Greek , which is the nodular accumulation of a soft, flaky, yellowish material at the center of large plaques, composed of macrophage s nearest the lumen anatomy lumen of the artery Underlying areas of cholesterol crystals Calcification at the outer base of older more advanced lesions. The following terms are similar, yet distinct, in both spelling and meaning, and can be easily confused arteriosclerosis , arteriolosclerosis , and atherosclerosis. Arteriosclerosis is a gener ... more details
Encyclopedia
top
